Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

ResMed’s stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.